194 related articles for article (PubMed ID: 8495416)
1. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen.
Abe-Hashimoto J; Kikuchi T; Matsumoto T; Nishii Y; Ogata E; Ikeda K
Cancer Res; 1993 Jun; 53(11):2534-7. PubMed ID: 8495416
[TBL] [Abstract][Full Text] [Related]
2. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia.
Abe J; Nakano T; Nishii Y; Matsumoto T; Ogata E; Ikeda K
Endocrinology; 1991 Aug; 129(2):832-7. PubMed ID: 1855478
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of 22-oxacalcitriol on estrogen receptor-negative MDA-MB-231 tumors in athymic mice.
Matsumoto H; Iino Y; Koibuchi Y; Andoh T; Horii Y; Takei H; Horiguchi J; Maemura M; Yokoe T; Morishita Y
Oncol Rep; 1999; 6(2):349-52. PubMed ID: 10023003
[TBL] [Abstract][Full Text] [Related]
4. Immune-deficient animals to study "hormone-dependent" breast and endometrial cancer.
Jordan VC; Gottardis MM; Robinson SP; Friedl A
J Steroid Biochem; 1989; 34(1-6):169-76. PubMed ID: 2626014
[TBL] [Abstract][Full Text] [Related]
5. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro.
Lindner DJ; Borden EC
J Interferon Cytokine Res; 1997 Nov; 17(11):681-93. PubMed ID: 9402106
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen.
Vink-van Wijngaarden T; Pols HA; Buurman CJ; van den Bemd GJ; Dorssers LC; Birkenhäger JC; van Leeuwen JP
Cancer Res; 1994 Nov; 54(21):5711-7. PubMed ID: 7923220
[TBL] [Abstract][Full Text] [Related]
8. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
9. Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia.
Endo K; Katsumata K; Iguchi H; Kubodera N; Teramoto T; Ikeda K; Fujita T; Ogata E
J Bone Miner Res; 1998 Sep; 13(9):1378-83. PubMed ID: 9738509
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
[TBL] [Abstract][Full Text] [Related]
11. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
12. [Antitumor activity of miproxifene phosphate (TAT-59) against human mammary carcinoma].
Toko T; Saito H; Fujioka A; Nukatuka M; Sato K; Hashimoto A; Shibata J; Yamada Y
Gan To Kagaku Ryoho; 1998 May; 25(6):829-38. PubMed ID: 9617321
[TBL] [Abstract][Full Text] [Related]
13. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human interferon-alpha 2a increases hormone receptor level of a human breast carcinoma xenograft in nude mice and enhances the anti-proliferative activity of tamoxifen.
Josui K; Kubota T; Kitajima M
Jpn J Cancer Res; 1992 Dec; 83(12):1347-53. PubMed ID: 1483948
[TBL] [Abstract][Full Text] [Related]
15. [Experimental chemo- and chemoendocrine therapy of human breast carcinomas serially transplanted into nude mice].
Koh J
Nihon Geka Gakkai Zasshi; 1988 Jan; 89(1):91-102. PubMed ID: 3129645
[TBL] [Abstract][Full Text] [Related]
16. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
17. Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse.
Gibson DF; Johnson DA; Goldstein D; Langan-Fahey SM; Borden EC; Jordan VC
Breast Cancer Res Treat; 1993; 25(2):141-50. PubMed ID: 8347846
[TBL] [Abstract][Full Text] [Related]
18. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Osipo C; Gajdos C; Cheng D; Jordan VC
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
[TBL] [Abstract][Full Text] [Related]
19. [Experimental combined chemo- and endocrine therapy with UFT and tamoxifen in human breast carcinoma xenografts serially transplanted into nude mice].
Kubota T; Josui K; Ishibiki K; Abe O; Yamada Y; Asanuma F; Kawamura E; Koh J; Shiina E
Nihon Gan Chiryo Gakkai Shi; 1990 Dec; 25(12):2767-73. PubMed ID: 2074386
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
